Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib
Drug Design, Development and Therapy · 2023-11 · Volume 17 · 3429-3437
DOI: 10.2147/dddt.s426898 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2023-11. Verfasst von Shiting Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Inner Mongolia Baogang Hospital, Baotou City, Inner, Mongolia, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug-Related Side Effects and Adverse Reactions, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Inner Mongolia Baogang Hospital, Baotou City, Inner, Mongolia, People's Republic of China.
Zitieren
APA
Li, S., & Wang, H. (2023). Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib. Drug Design, Development and Therapy, Volume 17, 3429-3437. https://doi.org/10.2147/dddt.s426898
Vancouver
Li S, Wang H. Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib. Drug Design, Development and Therapy. 2023;Volume 17:3429-3437. doi:10.2147/dddt.s426898
BibTeX
@article{Li2023,
author = {Li, Shiting and Wang, Hongqin},
title = {Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib},
journal = {Drug Design, Development and Therapy},
year = {2023},
volume = {Volume 17},
pages = {3429--3437},
doi = {10.2147/dddt.s426898}
}
EUVIMED